InMed Pharmaceuticals names new chief financial officer
5 August 2019 -

InMed Pharmaceuticals Inc (TSX:IN;OTCQX:IMLFF), a biopharmaceutical company, announced on Friday that it has named Bruce S Colwill, CPA, CA as its new chief financial officer, effective 9 August 2019.

Colwill joins InMed with more than 25 years of experience in financial leadership roles. Prior to InMed, Colwill served as chief financial officer of General Fusion Inc. Earlier, he was chief financial officer at Entree Resources Inc (TSX:ETG; NYSE American:EGI) from February 2011 to March 2016. He has also held chief financial officer roles at Neuromed Pharmaceuticals Ltd, Response Biomedical Corp, Forbes Medi-Tech Inc and Euronet Services Inc.

Eric A Adams, Inmed president and chief executive officer, said, 'We are delighted to have Mr Colwill join the InMed leadership team at a pivotal time for the Company. As the CFO of multiple public and private companies, Mr Colwill has executed a successful IPO as well as multiple equity and debt financings. His financial expertise and deep understanding of the capital markets will help ensure that InMed maintains a healthy balance sheet while continuing to execute on our broader strategic objectives.'